• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $KRTX

    Karuna Therapeutics Inc.

    Subscribe to $KRTX
    $KRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that has completed Phase II clinical trial for the treatment of acute psychosis in patients with schizophrenia; and in Phase Ib clinical trial for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of dementia-related psychosis. The company also focuses on developing other muscarinic-targeted drug candidates. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

    IPO Year: 2019

    Exchange: NASDAQ

    Website: karunatx.com

    Recent Analyst Ratings for Karuna Therapeutics Inc.

    DatePrice TargetRatingAnalyst
    12/12/2023$291.00Buy
    Citigroup
    12/12/2023$227.00Buy
    Deutsche Bank
    8/22/2023$225.00Overweight
    Wells Fargo
    7/20/2023$280.00Overweight
    Morgan Stanley
    3/8/2023$214.00Neutral
    Cantor Fitzgerald
    1/27/2023$209.00Neutral
    UBS
    1/5/2023$285.00Overweight
    Piper Sandler
    11/1/2022$288.00Buy
    Loop Capital
    7/14/2022$170.00Outperform
    SVB Leerink
    3/31/2022$190.00Buy
    Berenberg
    See more ratings